FELIX study results reveal obe-cel's potential in relapsed B-cell ALL, achieving 77% remission with low severe toxicity, enhancing CAR T-cell therapy outcomes.

Gerresheimer builds new production capacities for glass syringes at Skopje site Expansion of the site in the Republic of North Macedonia with a new production hall for glass syringes Düsseldorf/Skopje ...

Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute ...